Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
百妥平
- Development stage
- Phase 4
- Lead developer
- 北京百奥药业
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**百妥平** is an approved oral fixed-dose combination tablet developed by Beijing Baiao Pharmaceutical for the treatment of type 2 diabetes mellitus. The product contains **empagliflozin** and **metformin**, combining an SGLT2 inhibitor that reduces renal glucose reabsorption and increases urinary glucose excretion with a biguanide antihyperglycemic agent that decreases hepatic glucose production and improves insulin sensitivity. It is a small-molecule combination product marketed in tablet form for glycemic control in adults with type 2 diabetes mellitus.
- Brand names
- 百妥平
- Other names
- 二甲双胍恩格列净片二甲双胍恩格列净片(I)metformin + empagliflozinmetformin + empagliflozin tabletsBaituo Ping
02
Targets
SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on 百妥平.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 百妥平.